Overall, these are the most promising FDA‐approved drugs that greatly inhibit SRC and, thus, their experimental validation is of particular interest and highly advisable since CD as well as IBS patients would benefit from this dual targeting in clinical practice. This evidence concerns the gene SRC and irritable bowel syndrome.